Pharmacological interventions targeting this system, including AT1R antagonists and MasR agonists, have shown potential to reduce microglial activation, restore brain homeostasis, and slow the progression of diseases such as AD and PD. This evidence concerns the gene MAS1L and Parkinson disease.